Neuphoria Therapeutics said it terminated its Merck-partnered Phase II Alzheimer’s study of MK-1167 after the trial was marked “terminated for business reasons” on ClinicalTrials.gov, putting the future of its CHRNA7 modulator program under scrutiny. The update arrived without a formal press release, leaving investors to parse the implications from the trial status change. The discontinuation changes the immediate outlook for Neuphoria’s efforts in Alzheimer’s, and it also raises questions about how the CHRNA7 mechanism will be assessed going forward. The report noted that broader clinic updates were limited around the same period. For biotech teams, the episode is another reminder that clinical narratives can shift quickly even without immediate efficacy or safety readouts, particularly when partnership timelines and portfolio strategy intersect.